PMID- 30638932
OWN - NLM
STAT- MEDLINE
DCOM- 20191107
LR  - 20210215
IS  - 1090-2104 (Electronic)
IS  - 0006-291X (Linking)
VI  - 509
IP  - 4
DP  - 2019 Feb 19
TI  - TIPE2 in dendritic cells inhibits the induction of pTregs in the gut mucosa.
PG  - 911-917
LID - S0006-291X(19)30008-7 [pii]
LID - 10.1016/j.bbrc.2019.01.008 [doi]
AB  - Dendritic cells (DCs) are professional antigen-presenting cells. The main 
      function of DCs is to process antigen and present it to the T cells to induce T 
      cell immunity. In addition to their function as potent stimulators of adaptive 
      immunity, DCs are also crucial for maintaining immunological tolerance through 
      the induction of peripheral regulatory T cells. Tumor necrosis factor-alpha-induced 
      protein 8-2 (Tumor necrosis factor-alpha induced protein-8-like 2, TNFAIP8L2 or 
      TIPE2) was expressed primarily by immune cells and maintains immune tolerance 
      through the negative regulation of innate and adaptive immune responses. Previous 
      studies indicate that TIPE2 in DCs may inhibit the innate immune response to RNA. 
      However, the role of TIPE2 in DCs in the induction of peripheral tolerance 
      remains unknown. Our current study showed that Tipe2-deficient DCs are more 
      immature under homeostatic condition and consequently promote the induction of 
      peripheral Tregs in the gut mucosa. Mechanistic studies revealed that TIPE2 
      promotes the expression of DC maturation markers CD80 and CD86 through the 
      activation of PI3K-PKCdelta-MAPK signaling pathway during the differentiation of DCs. 
      Taken together, these results indicate that, in addition to acting as a negative 
      regulator of pathogen-induced immune response, TIPE2 in DCs is also capable of 
      promoting immune response under homeostatic condition through the suppression of 
      peripheral tolerance.
CI  - Copyright (c) 2019 Elsevier Inc. All rights reserved.
FAU - Liu, Ruiling
AU  - Liu R
AD  - Center for Antibody Drug, Institute of Biomedicine and Biotechnology, Shenzhen 
      Institutes of Advanced Technology, Chinese Academy of Sciences, Shenzhen, 518055, 
      People's Republic of China; University of Chinese Academy of Sciences, Beijing, 
      100049, People's Republic of China.
FAU - Liu, Cuilian
AU  - Liu C
AD  - Center for Antibody Drug, Institute of Biomedicine and Biotechnology, Shenzhen 
      Institutes of Advanced Technology, Chinese Academy of Sciences, Shenzhen, 518055, 
      People's Republic of China.
FAU - Liu, Chaoyu
AU  - Liu C
AD  - Center for Antibody Drug, Institute of Biomedicine and Biotechnology, Shenzhen 
      Institutes of Advanced Technology, Chinese Academy of Sciences, Shenzhen, 518055, 
      People's Republic of China; Jinan University, Guangzhou, 510632, People's 
      Republic of China.
FAU - Fan, Tingting
AU  - Fan T
AD  - Center for Antibody Drug, Institute of Biomedicine and Biotechnology, Shenzhen 
      Institutes of Advanced Technology, Chinese Academy of Sciences, Shenzhen, 518055, 
      People's Republic of China; University of Chinese Academy of Sciences, Beijing, 
      100049, People's Republic of China.
FAU - Geng, Wenwen
AU  - Geng W
AD  - Center for Antibody Drug, Institute of Biomedicine and Biotechnology, Shenzhen 
      Institutes of Advanced Technology, Chinese Academy of Sciences, Shenzhen, 518055, 
      People's Republic of China.
FAU - Ruan, Qingguo
AU  - Ruan Q
AD  - Center for Antibody Drug, Institute of Biomedicine and Biotechnology, Shenzhen 
      Institutes of Advanced Technology, Chinese Academy of Sciences, Shenzhen, 518055, 
      People's Republic of China; Shandong Provincial Key Laboratory of Ophthalmology, 
      Shandong Eye Institute, Shandong Academy of Medical Sciences, Qingdao, 266071, 
      People's Republic of China. Electronic address: qg.ruan@siat.ac.cn.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20190111
PL  - United States
TA  - Biochem Biophys Res Commun
JT  - Biochemical and biophysical research communications
JID - 0372516
RN  - 0 (Intracellular Signaling Peptides and Proteins)
RN  - 0 (TNFAIP8L2 protein, human)
RN  - EC 2.7.- (Protein Kinases)
SB  - IM
MH  - Animals
MH  - Cell Differentiation/drug effects
MH  - Cells, Cultured
MH  - Dendritic Cells/*immunology
MH  - Homeostasis
MH  - Humans
MH  - Immune Tolerance/drug effects
MH  - Immunity, Innate/drug effects
MH  - Intestinal Mucosa/*immunology
MH  - Intracellular Signaling Peptides and Proteins/*pharmacology
MH  - Protein Kinases/drug effects/metabolism
MH  - Signal Transduction
MH  - T-Lymphocytes, Regulatory/*immunology
MH  - Transcriptional Activation/drug effects/*immunology
OTO - NOTNLM
OT  - Dendritic cells
OT  - Peripheral tolerance
OT  - TIPE2
OT  - pTreg
EDAT- 2019/01/15 06:00
MHDA- 2019/11/08 06:00
CRDT- 2019/01/15 06:00
PHST- 2018/12/21 00:00 [received]
PHST- 2019/01/03 00:00 [accepted]
PHST- 2019/01/15 06:00 [pubmed]
PHST- 2019/11/08 06:00 [medline]
PHST- 2019/01/15 06:00 [entrez]
AID - S0006-291X(19)30008-7 [pii]
AID - 10.1016/j.bbrc.2019.01.008 [doi]
PST - ppublish
SO  - Biochem Biophys Res Commun. 2019 Feb 19;509(4):911-917. doi: 
      10.1016/j.bbrc.2019.01.008. Epub 2019 Jan 11.